title: [Indications for castration in women treated for breast cancer].
abstract: Historically, castration has been the first endocrine treatment in breast carcinoma. In premenopausal metastatic patients, castration improves quality of survival during a median period of 10 months, in one third of patients. As adjuvant treatment, prophylactic castration can be an alternative to chemotherapy in patients with positive receptors. Prospective randomized trials are being conducted to define indications of each adjuvant treatment.
authors.affiliation: Clinique d'Oncologie et Radiothérapie, CHU, Tours.
authors.forename: S
authors.initials: S
authors.lastname: Chapet
authors.forename: A R
authors.initials: AR
authors.lastname: Bougnoux
authors.forename: C
authors.initials: C
authors.lastname: Berger
authors.forename: P
authors.initials: P
authors.lastname: Descamps
authors.forename: G
authors.initials: G
authors.lastname: Body
authors.forename: G
authors.initials: G
authors.lastname: Calais
authors.forename: P
authors.initials: P
authors.lastname: Bougnoux
authors.forename: O
authors.initials: O
authors.lastname: Le Floch
authors.forename: J
authors.initials: J
authors.lastname: Lansac
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D010052:Ovariectomy; D018579:Patient Selection; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal